Balixafortide (POL6326) is primarily used in the field of oncology as a CXCR4 antagonist. It is being investigated for its potential to enhance the efficacy of chemotherapy in treating breast cancer. By blocking the CXCR4 receptor, it may help in preventing cancer cells from migrating and invading other tissues, thereby reducing metastasis. Additionally, it is being explored in combination therapies to improve the mobilization of hematopoietic stem cells for transplantation in patients with certain blood disorders. Its role in disrupting the tumor microenvironment also makes it a promising candidate for further cancer research and treatment strategies.